Publication Year

Chappell G, Welsh B, Harvey S, Harris M, Wikoff D. Validation and application of a text mining tool in the identification and categorization of mechanistic data: A case study in improving problem formulation of carcinogenicity assessments. Poster presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.

Proctor DM, Suh M, Dunsmore D, Verwiel A, Casteel S. 2017. Bioaccessibility and relative oral bioavailability of cobalt and nickel from metal alloys in soil and dust. Poster presented at Society of Toxicology Annual Meeting, March 15, Baltimore, MD.

Kirman CR, Proctor D, Suh M, Haws L, Harris M, Thompson C, Hays S. Using physiologically based pharmacokinetic modeling to address potentially sensitive subpopulations exposed to hexavalent chromium. Poster presented at 56th Society of Toxicology Annual Meeting, Baltimore, MD, March 2017.

Rager JE, Thompson CM, Ring C, Fry RC, Harris MA. Integration of transcriptomics and high-throughput screening predictions with robust in vivo data to inform hexavalent chromium mode of action. Poster presented at Society of Toxicology Annual Meeting, Baltimore, MD, March 2017.

Thompson C, Kirman C, Suh M, Proctor D, Haws L, Harris M, Hays S. 2017. Risk assessment of oral exposure to Cr(VI): Integration of mode of action, pharmacokinetics, and dose-response modeling. Poster presented at Society of Toxicology Annual Meeting, March 14, Baltimore, MD.

Mease K, Kimzey A, Lansita J. 2017. Failed dose formulation analysis during a GLP study — Now what? Poster presented at Society of Toxicology Annual Meeting, March 14, Baltimore, MD.

Suh M, Harvey S, Wikoff D, Mittal L, Ring C, Goodmanson A, Proctor D. Meta-analysis of hexavalent chromium and stomach cancer. Poster presented at Society of Toxicology 56th Annual Meeting, March 13, Baltimore, MD, March 2017.

Covington TR, Pangburn HA, Mayes RS, Ott DK, Gearhart JM. Estimated inter-individual variations in high-performance aircraft pilot exposures using physiologically-based pharmacokinetic (PBPK) modeling and Monte Carlo analysis. Poster presented at the Society of Toxicology Annual Meeting, Baltimore, MD, March 2017.

Haber LT, Bates HK, Allen BC, Vincent MJ, Oller AR. 2017. Derivation of an oral toxicity reference value for nickel. Regul Toxicol Pharmacol 87(S1–S18), doi: 10.1016/j.yrtph.2017.03.011.

Vincent MJ, Parker A, Maier A. 2017. Cleaning and asthma: A systematic review and approach for effective safety assessment. Regul Toxicol Pharmacol 90:231–243, doi: 10.1016/j.yrtph.2017.09.013.

Vincent MJ, Bernstein JA, Basketter D, LaKind JS, Dotson GS, Maier A. 2017. Chemical-induced asthma and the role of clinical, toxicological, exposure and epidemiological research in regulatory and hazard characterization approaches. Regul Toxicol Pharmacol 90:126–132, doi: 10.1016/j.yrtph.2017.08.018.

Ceger P, Choksi N, Hamm J, Truax J, Daniel A, Allen D, et al. Development of a curated database of in vivo developmental toxicity data. Poster presented at Society of Toxicology Annual Meeting, Baltimore, MD, March 2017.

Buerger AN, Schmidt J, Paixao C, Tiblier A, Martyniuk CJ, Bisesi JH. Does oral exposure to phthalates alter obesity related transcriptional networks in the gastrointestinal system through PPARα? Society of Toxicology Meeting, 2017.

Buerger AN, Schmidt J, Martyniuk CJ, Bisesi JH. Host-microbiome responses to DEHP exposure: A multigenerational obesity study in Danio rerio. Society of Environmental Toxicology and Chemistry North America Meeting, 2017.

Lynch M, Brown L, Chiger A. Case studies for neurotoxic chemicals. Presentation to Society for Risk Analysis, San Diego, CA, 2017.

Morgan SJ, Couch J, Guzzie-Peck P, Keller DA, Kemper R, Otieno MA, Schulingkamp RJ, Jones TW. 2017. Regulatory forum opinion piece: Use and utility of animal models of disease for nonclinical safety assessment: A pharmaceutical industry survey. Toxicol Pathol 45(3):372–380, doi: 10.1177/0192623317701004.

Prescott JS, Andrews PA, Baker RW, Bogdanffy MS, Fields FO, Keller DA, Lapadula DM, Mahoney NM, Paul DE, Platz SJ, Reese DM, Stoch SA, DeGeorge JJ. 2017. Evaluation of therapeutics for advanced-stage heart failure and other severely-debilitating or life-threatening diseases. Clin Pharmacol Ther 102(2):219–227, doi: 10.1002/cpt.730.

Ewart L, Fabre K, Chakilam A, Dragan Y, Duignan DB, Eswaraka J, Gan J, Guzzie-Peck P, Otieno M, Jeong CG, Keller DA, de Morais SM, Phillips JA, Proctor W, Sura R, Van Vleet T, Watson D, Will Y, Tagle D, Berridge B. 2017. Navigating tissue chips from development to dissemination: A pharmaceutical industry perspective. Exp Biol Med (Maywood) 242(16):1579–1585, doi: 10.1177/1535370217715441.

Monticello TM, Jones TW, Dambach DM, Potter DM, Bolt MW, Liu M, Keller DA, Hart TK, Kadambi VJ. 2017. Current nonclinical testing paradigm enables safe entry to first-in-human clinical trials: The IQ consortium nonclinical to clinical translational database. Toxicol Appl Pharmacol 334:100–109, doi: 10.1016/j.taap.2017.09.006.

Frankenfeld CL. Human gut microbiome and health. University of Maryland, Maryland Institute of Applied Environmental Health, May 5, 2017.